They discovered that, in contrast to MTAP gene intact BC, 650 advanced BC samples (24.2%) had MTAP loss, with frequent co-deletions of CDKN2A/B, co-mutations with FGFR3, and co-mutations with phosphatase and tensin homolog genes, which all contributed to developing new synthetic lethality targeted therapies (38). Here, CDKN2A is linked to breast cancer.